Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| RitonavirNCT00122577 | French National Agency for Research on AIDS and Viral HepatitisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-07-28 |
| AtazanavirNCT00122577 | French National Agency for Research on AIDS and Viral HepatitisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-07-28 |
| TenofovirNCT00122577 | French National Agency for Research on AIDS and Viral HepatitisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-07-28 |
| edifoligide (E2F Decoy)NCT00086164 | Anesiva, Inc.PHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-07-19 |
| iseganan hydrochlorideNCT00118781 | IntraBiotics PharmaceuticalsPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2005-07-19 |
| Ecraprost in lipid emulsionNCT00059644 | Tanabe Pharma CorporationPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| Hemolink (hemoglobin raffimer IV solution)NCT00038454 | HemosolPHASE2, PHASE3 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| MTC-DOX for InjectionNCT00034333 | FeRxPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| AlbuterolNCT00005110 | National Center for Research Resources (NCRR)NA | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| SalmeterolNCT00005110 | National Center for Research Resources (NCRR)NA | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| RibavirinNCT00002298 | ICN PharmaceuticalsNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| StavudineNCT00002424 | Merck Sharp & Dohme LLCPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| LamivudineNCT00002424 | Merck Sharp & Dohme LLCPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| Indinavir sulfateNCT00002424 | Merck Sharp & Dohme LLCPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| L-756423NCT00002424 | Merck Sharp & Dohme LLCPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| PEG-paclitaxelNCT00023166 | Enzon Pharmaceuticals, Inc.PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| doxorubicin intravenousNCT00057382 | TularikPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| T138067 intravenousNCT00057382 | TularikPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| leucineNCT00014768 | National Center for Research Resources (NCRR)Phase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| insulinNCT00014768 | National Center for Research Resources (NCRR)Phase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| glucoseNCT00014768 | National Center for Research Resources (NCRR)Phase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| implitapideNCT00080132 | Medical Research Laboratories InternationalPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| StavudineNCT00002362 | Triangle PharmaceuticalsPHASE3 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| EmtricitabineNCT00002362 | Triangle PharmaceuticalsPHASE3 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
| EfavirenzNCT00002362 | Triangle PharmaceuticalsPHASE3 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-06-24 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |